Walvax Biotechnology Co., Ltd. (SHE:300142)

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Autonomous Vaccine	4.08B
Intermediate Products	17.22M
Intermediate Products Growth	-36.61%
Technical Services	11.02M
Technical Services Growth	-33.40%
Other Business	7.92M
Other Business Growth	3.51%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	3.83B
China Growth	-20.34%
Overseas	287.54M
Overseas Growth	1.46%